I like Dr Patterson as much as the next long investor with

New Post Public Reply Private Reply Replies (0) Message Board
Goosebumps TechGuru #84382
550
I like Dr Patterson as much as the next long investor with CYDY. He was my hard hook that landed me here in CYDY land. What I remember most is the comment in his Tedx talk that Leronlimab acts like it a has almost been designed for covid it would seem and all other drugs will have to be used together as piece meal to get any results like Leronlimab. So, where does he stand now? Since he can’t use it as of right now until approved.

I watched his latest video yesterday with Dr. Yo and a couple of IncellDX employees and they were hashing out costs of their trial from written questions from the viewers. Justifying the costs of the lab work mostly.

Dr. Patterson did speak of a combination of drugs and as I remember one was ivermectin as an immune modulator included in this 3 drug group to be used. Maybe ivermectin will finally get its due recognition from the FDA and it has good or great use for COVID-19. The majority of scientists do not support it currently. It makes you wonder if Dr. Patterson is cutting edge or falling behind on treatment with using a drug not recognized as usable by the FDA. It appears in order to be relevant in their online suggestive clinic he is using what he himself said is piece meal of drugs to do what the 3 functions of Leronlimab are. It was Dr. Patterson that stated this in his Tedx talk that all other drugs for covid are piece meal. Since he can’t use Leronlimab in his clinic... is he stuck with just piece meal? Would he change his tune and add or exclusively use Leronlimab in his clinic? Because when he explained the use of the 3 drugs he was using. It sounded like they add up to what Leronlimab was suggested to do. By none other than Dr. Patterson.

His short video stating this is below. I realize this is 7 months ago and Long Haulers wasn’t even a blip on the screen yet. But in my view, the trial to show dosing for LH is acceptable for the information it will provide. Being injected weekly may be the answer for any indication of covid. How long might be the real question. I am hoping for great things with 8 weekly injections. We may find out that LH is just like HIV and you have to be on it forever. Not likely but who really knows. That maybe, you only keep the virus away with weekly or monthly injections. The trial will tell us what we need to know. Before we jump in to bed with another drug and see what combination might work the best for LH. We should see what we do on our own. That’s just my opinion. I respect your opinion TechGuru. I would like to see what we can do in this short trial first is all.

https://youtu.be/uSfzhwkByf0

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 100

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 279

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 155

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 128

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 140

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 125

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 201

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 198

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 84

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 10

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading

Top 5 Most Recently Viewed Articles

City Office REIT's 2024 Q3 Performance and Strategic Outlook

Updated Category News Views 266

City Office REIT's Third Quarter 2024 Financial Results Overview City Office REIT, Inc. (NYSE: CIO) has recently released its financial results for the third quarter of 2024. In this quarter's report, the company highlighted a substantial progression in its office real estate fundamentals, showcasing resilience and strategic maneuvers in a competitive market. Key...

Continue Reading
Latest Transactions of Ringkjøbing Landbobank A/S Shares

Updated Category News Views 146

Overview of Share Transactions In the realm of financial regulations, the duty of disclosure plays a crucial role. When it comes to transactions involving shares, companies must adhere to specific guidelines to maintain transparency. Recently, Ringkjøbing Landbobank A/S has reported its share transactions, which is particularly important for stakeholders, regulatory...

Continue Reading
Unlocking Success: The Power of Trust in Business Practices

Updated Category News Views 280

Trust as the Foundation of Business Success Recent insights have emerged showing that trust not only fosters a positive workplace culture but also serves as a significant catalyst for long-term financial prosperity. According to research from Great Place To Work®, companies that prioritize trust within their employee relationships consistently outperform their...

Continue Reading
Investing in Texas Instruments: A 15-Year Journey of Growth

Updated Category News Views 126

The Impressive Growth of Texas Instruments Texas Instruments (NASDAQ: TXN), a leader in semiconductor technology, has demonstrated remarkable performance over the last 15 years. With an annualized return of 15.69%, it has surpassed market averages by 3.27%. This kind of consistent growth illustrates why many investors find TXN appealing. Your $1000 Investment in TXN If an...

Continue Reading
Sarah Schmelzel Joins SERVPRO as New Brand Ambassador

Updated Category News Views 414

Sarah Schmelzel Becomes a SERVPRO Brand Ambassador Gallatin, Tennessee – SERVPRO, a well-regarded leader in cleanup, restoration, and construction, proudly announces the partnership with LPGA golfer Sarah Schmelzel as a brand ambassador for the upcoming season. This collaboration underscores SERVPRO’s deep-rooted involvement with top-tier sports organizations,...

Continue Reading